Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stereotactic radiosurgery yields higher overall survival in patients with RCC metastatic to the brain

Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015

Key clinical point: Treatment with stereotactic radiosurgery was superior to non-stereotactic radiotherapy for overall survival in patients with renal cell carcinoma metastatic to the brain.

Major finding: Higher overall survival was observed in the stereotactic radiosurgery cohort both before and following propensity matching. On subset analysis, differences persisted when stratifying for nephrectomy (p<0.001 for all). Treatment at an academic center independently predicted a higher rate of overall survival.

Study details: Data for 2005-2014 in the National Cancer Data Base for metastatic RCC and delivery of intracranial radiotherapy found 2,312 patients, 813 (35%) of whom received SRS and 1,499 of whom received non-SRS radiotherapy. Use of SRS increased from 27% in 2005 to 44% in 2014, and was less often given to low income and uninsured/Medicaid patients (p<0.05).

Disclosures: The researchers had no relevant financial disclosures.

Source: Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015

Citation:

Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015

This Week's Must Reads

Treatable RCC among patients with cancers of unknown primary site, Greco F & Hainsworth J. Clinical Genitourinary Cancer (Available online 9 March 2018). https://doi.org/10.1016/j.clgc.2018.03.001

Poorer RCC outcomes with incidental pathologic T3a upstaging at partial nephrectomy, Russell C et al. Urology (published online 17 April 2018) https://doi.org/10.1016/j.urology.2018.04.002

Renal percutaneous irreversible electroporation tested in pT1a RCC, Wendler J et al. Urology 2018 (114): 224–32. https://doi.org/10.1016/j.urology.2017.12.016

Nivolumab plus ipilimumab approved for advanced RCC, FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm604685.htm

Triple VEGF inhibitor for recalcitrant RCC, Molina AM, et al. Eur J Cancer. 2018 Mar 13. doi: 10.1016/j.ejca.2018.02.009.

Must Reads in Renal Cell Carcinoma

Treatable RCC among patients with cancers of unknown primary site, Greco F & Hainsworth J. Clinical Genitourinary Cancer (Available online 9 March 2018). https://doi.org/10.1016/j.clgc.2018.03.001

Poorer RCC outcomes with incidental pathologic T3a upstaging at partial nephrectomy, Russell C et al. Urology (published online 17 April 2018) https://doi.org/10.1016/j.urology.2018.04.002

Renal percutaneous irreversible electroporation tested in pT1a RCC, Wendler J et al. Urology 2018 (114): 224–32. https://doi.org/10.1016/j.urology.2017.12.016

Nivolumab plus ipilimumab approved for advanced RCC, FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm604685.htm

Triple VEGF inhibitor for recalcitrant RCC, Molina AM, et al. Eur J Cancer. 2018 Mar 13. doi: 10.1016/j.ejca.2018.02.009.